The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders Publisher Pubmed

Payandeh Z¹ ; Bahrami AA² ; Hoseinpoor R² ; Mortazavi Y^{3, 7} ; Rajabibazl M^{4, 5} ; Rahimpour A⁵ ; Taromchi AH³ ; Khalil S⁶

Source: Biomedicine and Pharmacotherapy Published:2019

Abstract

B-lymphocyte antigen CD20 (called CD20) is known as an activated-glycosylated phosphoprotein which is expressed on the surface of all B-cells. CD20 is involved in the regulation of trans-membrane Ca 2+ conductance and also play critical roles in cell‐cycle progression during human B cell proliferation and activation. The appearance of monoclonal antibody (mAb) technology provided an effective field for targeted therapy in treatment of a variety of diseases such as cancer, and autoimmune diseases. Anti-CD20 is one of important antibodies which could be employed in treatment of several diseases. Increasing evidences revealed that efficacy of different anti-CD20 antibodies is implicated by their function. Hence, evaluation of anti-CD20 antibodies function could provide and introduce new anti-CD20 based therapies. In the present study, we summarized several applications of anti-CD20 antibodies in various immune related disorders including B-CLL (B-cell chronic lymphocytic leukemia), rheumatoid arthritis (RA), multiple sclerosis (MS) and melanoma. © 2018

Related Docs

View other Related Docs

1. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

2. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)

3. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (6)

Gholamreza Toogeh (1)

Other Related Docs

4. In Silico Analysis for Determination and Validation of Human Cd20 Antigen 3D Structure, International Journal of Peptide Research and Therapeutics (2019)

5. B Cells in Multiple Sclerosis Therapy—A Comprehensive Review, Acta Neurologica Scandinavica (2018)

6. Immune Therapy of Melanoma: Overview of Therapeutic Vaccines, Journal of Cellular Physiology (2019)

7. Cancer Stem Cell-Targeted Chimeric Antigen Receptor (Car)-T Cell Therapy: Challenges and Prospects, Acta Pharmaceutica Sinica B (2021)

8. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)

9. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)

10. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)

11. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)

12. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)

13. Synergistic Induction of Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells After Treatment With All-Trans Retinoic Acid in Combination With Interleukin-21 and Rituximab, Journal of Cancer Research and Therapeutics (2016)

14. Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies, Cells (2021)

15. A Review on Leukemia and Ipsc Technology: Application in Novel Treatment and Future, Current Stem Cell Research and Therapy (2018)

16. A Double-Blind, Randomized Comparison Study Between Zytux™ Vs Mabthera® in Treatment of Cll With Fcr Regimen: Non-Inferiority Clinical Trial, International Journal of Hematology-Oncology and Stem Cell Research (2018)

17. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

18. Tumor Immunology, Clinical Immunology (2022)

19. Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using Bi-Specific Antibodies and Therapeutic Vaccines, Biological Procedures Online (2021)

20. Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma, Expert Review of Anticancer Therapy (2015)

Style	Citing Format
MLA	Payandeh Z, et al.. "The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders." Biomedicine and Pharmacotherapy, vol. 109, no. , 2019, pp. 2415-2426.
APA	Payandeh Z, Bahrami AA, Hoseinpoor R, Mortazavi Y, Rajabibazl M, Rahimpour A, Taromchi AH, Khalil S (2019). The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders. Biomedicine and Pharmacotherapy, 109(), 2415-2426.
Chicago	Payandeh Z, Bahrami AA, Hoseinpoor R, Mortazavi Y, Rajabibazl M, Rahimpour A, Taromchi AH, Khalil S. "The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders." Biomedicine and Pharmacotherapy 109, no. (2019): 2415-2426.
Harvard	Payandeh Z et al. (2019) 'The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders', Biomedicine and Pharmacotherapy, 109(), pp. 2415-2426.
Vancouver	Payandeh Z, Bahrami AA, Hoseinpoor R, Mortazavi Y, Rajabibazl M, Rahimpour A, et al.. The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders. Biomedicine and Pharmacotherapy. 2019;109():2415-2426.
BibTex	@article{ author = {Payandeh Z and Bahrami AA and Hoseinpoor R and Mortazavi Y and Rajabibazl M and Rahimpour A and Taromchi AH and Khalil S}, title = {The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders}, journal = {Biomedicine and Pharmacotherapy}, volume = {109}, number = {}, pages = {2415-2426}, year = {2019} }
RIS	TY - JOUR AU - Payandeh Z AU - Bahrami AA AU - Hoseinpoor R AU - Mortazavi Y AU - Rajabibazl M AU - Rahimpour A AU - Taromchi AH AU - Khalil S TI - The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders JO - Biomedicine and Pharmacotherapy VL - 109 IS - SP - 2415 EP - 2426 PY - 2019 ER -

Science Communicator Platform

Authors

Abstract